

Table of contents

| | | |
|--------------|---|-------------|
| | List of editors | III |
| | List of authors, contributors, editors and reviewers | V |
| | Literature Group | XII |
| | Prefaces | XIII |
| | Executive summary | XXXV |
| | Principles of evidence assessment and methods for reaching recommendations | XLIX |
| 1 | Introduction | 1 |
| | Guiding principles | 3 |
| | Recommendations and conclusions | 4 |
| 1.1 | Background | 6 |
| 1.1.1 | Colorectal cancer in Europe | 6 |
| 1.1.2 | Population screening for colorectal cancer | 7 |
| 1.1.3 | Principles of population screening | 7 |
| 1.1.4 | EU policy on cancer screening | 9 |
| 1.1.5 | Implementation of colorectal cancer screening in Europe | 11 |
| 1.2 | Evidence for effectiveness of FOBT screening | 12 |
| 1.2.1 | Guaiac FOBT | 12 |
| 1.2.1.1 | Evidence for efficacy | 12 |
| 1.2.1.2 | Evidence for the interval | 12 |
| 1.2.1.3 | Evidence for the age range | 13 |
| 1.2.1.4 | Evidence on risks vs. benefit and cost-effectiveness | 14 |
| 1.2.2 | Immunochemical FOBT | 14 |
| 1.2.2.1 | Evidence for efficacy | 14 |
| 1.2.2.2 | Evidence for the interval | 15 |
| 1.2.2.3 | Evidence for the age range | 15 |
| 1.2.2.4 | Evidence on risks vs. benefit and cost-effectiveness | 15 |
| 1.3 | Evidence for effectiveness of endoscopy screening | 16 |
| 1.3.1 | Sigmoidoscopy | 16 |
| 1.3.1.1 | Evidence for efficacy | 16 |
| 1.3.1.2 | Evidence for the interval | 17 |
| 1.3.1.3 | Evidence for the age range | 18 |
| 1.3.1.4 | Evidence on risks vs. benefit and cost-effectiveness | 18 |
| 1.3.2 | Colonoscopy | 19 |
| 1.3.2.1 | Evidence for efficacy | 19 |

| | | |
|--------------|--|-----------|
| 1.3.2.2 | Evidence for the interval | 20 |
| 1.3.2.3 | Evidence for the age range | 20 |
| 1.3.2.4 | Evidence on risks vs. benefit and cost-effectiveness | 20 |
| 1.4 | Evidence for effectiveness of FOBT and sigmoidoscopy combined | 21 |
| 1.5 | New screening technologies under evaluation | 22 |
| 1.5.1 | CT colonography | 22 |
| 1.5.2 | Stool DNA | 23 |
| 1.5.3 | Capsule endoscopy | 23 |
| 1.6 | References | 24 |

2

Organisation 33

| | | |
|--------------|--|-----------|
| | Guiding principles for organising a colorectal cancer screening programme | 35 |
| | Recommendations and conclusions | 36 |
| 2.1 | Introduction | 39 |
| 2.2 | Organised vs. non-organised screening | 39 |
| 2.2.1 | Opportunistic screening or case-finding | 40 |
| 2.2.2 | Comparison of coverage and effectiveness | 40 |
| 2.2.3 | Prerequisites for organised screening | 40 |
| 2.3 | Implementing the screening programme | 42 |
| 2.3.1 | Identifying and defining the target population | 42 |
| 2.3.1.1 | Inclusion and exclusion criteria | 43 |
| 2.3.1.2 | Family history | 43 |
| 2.4 | Participation in screening | 44 |
| 2.4.1 | Barriers | 44 |
| 2.4.2 | Interventions to promote participation | 45 |
| 2.4.2.1 | Removing financial barriers | 45 |
| 2.4.3 | Invitation | 46 |
| 2.4.3.1 | Invitation letter | 46 |
| 2.4.3.2 | Reminders | 46 |
| 2.4.3.3 | Delivering information about screening | 47 |
| 2.4.3.3.1 | Information conveyed with the invitation (see also Chapter 10) | 47 |
| 2.4.3.4 | The role of primary care providers | 48 |
| 2.4.3.4.1 | Role of GPs/family physicians | 48 |
| 2.4.3.4.2 | Interventions aimed to promote provider involvement (See also Chapter 10) | 49 |
| 2.5 | Testing protocol | 50 |
| 2.5.1 | FOBT | 50 |

| | | |
|--------------|--|-----------|
| 2.5.1.1 | Delivery of kits and collection of stool samples (see also Chapter 4) | 50 |
| 2.5.1.2 | Performing the test: dietary restrictions and number of samples | 51 |
| 2.5.1.3 | Examination of the samples, test interpretation and reporting | 51 |
| 2.5.2 | Endoscopy | 52 |
| 2.5.2.1 | Obtaining bowel preparation for endoscopy screening | 52 |
| 2.5.2.2 | Bowel preparation for sigmoidoscopy (see also Chapter 5) | 53 |
| 2.5.2.3 | Bowel preparation for colonoscopy (see also Chapter 5) | 53 |
| 2.5.2.4 | Test interpretation and reporting | 54 |
| 2.5.2.4.1 | Inadequate test | 54 |
| 2.5.2.4.2 | Defining a negative test and episode result | 54 |
| 2.5.3 | Management of people with positive test results and fail-safe mechanisms | 54 |
| 2.5.4 | Follow-up of population and interval cancers (see also Chapter 3) | 55 |
| 2.6 | Screening policy within the healthcare system | 56 |
| 2.6.1 | Local conditions at the start of a programme | 56 |
| 2.6.2 | Defining the relevant healthcare professional and facilities | 57 |
| 2.6.2.1 | Diagnostic and treatment centres | 57 |
| 2.6.2.2 | Public health specialists | 57 |
| 2.6.3 | What factors should be considered when deciding which primary test to use? | 58 |
| 2.6.3.1 | Gender and age differences (see also Chapter 1) | 58 |
| 2.6.3.2 | Participation | 58 |
| 2.6.3.3 | Screening interval and neoplasia detection rates according to the site distribution (see also Chapter 1) | 59 |
| 2.6.3.4 | Cost-effectiveness (see also Chapter 1) | 59 |
| 2.6.3.5 | Resources and sustainability of the programme | 60 |
| 2.6.4 | Implementation period (step-wise) | 60 |
| 2.6.5 | Data collection and monitoring (see also Chapter 3) | 61 |
| 2.6.5.1 | Data sources | 61 |
| 2.6.5.2 | How to respond to outcomes of monitoring | 62 |
| 2.7 | References | 63 |
| 3 | Evaluation and interpretation of screening outcomes | 71 |
| | Recommendations | 73 |
| 3.1 | Introduction | 75 |
| 3.2 | Data items necessary for evaluation | 76 |
| 3.2.1 | Programme conditions | 76 |
| 3.2.2 | Invitation variables | 77 |
| 3.2.3 | Process variables of primary screening and follow up | 77 |
| 3.2.3.1 | Process variables in screening with the faecal occult blood test (FOBT) and other in vitro tests | 77 |
| 3.2.3.2 | Variables in endoscopic screening | 78 |
| 3.2.4 | Programme outcome variables | 79 |

| | | |
|--------------|---|------------|
| 3.2.5 | Data tables | 80 |
| 3.3 | Early performance indicators | 81 |
| 3.3.1 | Programme coverage and uptake | 83 |
| 3.3.2 | Outcomes with faecal occult blood testing (FOBT) for primary screening | 84 |
| 3.3.3 | Outcomes with flexible sigmoidoscopy (FS) or colonoscopy (CS) as primary screening tests | 90 |
| 3.3.4 | Screening organisation | 95 |
| 3.4 | Long-term impact indicators | 96 |
| 3.4.1 | Interval cancers | 97 |
| 3.4.2 | CRC incidence rates | 98 |
| 3.4.3 | Rates of advanced-stage disease | 98 |
| 3.4.4 | CRC mortality rates | 98 |
| 3.5 | References | 100 |

4

Faecal Occult Blood Testing 103

| | | |
|--------------|--|------------|
| | Recommendations | 105 |
| 4.1 | Introduction | 109 |
| 4.2 | Biochemical tests for colorectal cancer | 110 |
| 4.2.1 | Characteristics of a test for population-screening of colorectal cancer | 110 |
| 4.2.2 | Faecal blood loss | 111 |
| 4.2.3 | Sample collection for Faecal Occult Blood Test devices | 111 |
| 4.2.4 | Guaiaac Faecal Occult Blood Test - gFOBT | 112 |
| 4.2.5 | Immunochemical tests - iFOBTs | 113 |
| 4.2.6 | Other tests | 114 |
| 4.2.7 | Recommendations | 115 |
| 4.3 | Analytical characteristics and performance | 116 |
| 4.3.1 | Analytical sensitivity | 116 |
| 4.3.1.1 | Analytical sensitivity and cut-off limits | 116 |
| 4.3.2 | Analytical specificity and interference | 117 |
| 4.3.2.1 | Analytical interference | 117 |
| 4.3.2.2 | Biological interference | 118 |
| 4.3.2.3 | Dietary and drug restrictions | 120 |
| 4.3.3 | Other factors influencing analytical performance | 121 |
| 4.3.3.1 | Prozone effect | 121 |
| 4.3.3.2 | Sample quality | 121 |
| 4.3.3.3 | Device consistency | 122 |
| 4.3.3.4 | Analytical quality assurance – Internal Quality Control (IQC) and External Quality Assessment Schemes (EQAS) | 122 |
| 4.3.4 | Recommendations | 126 |
| 4.4 | Clinical performance | 128 |

| | | |
|--------------|---|------------|
| 4.4.1 | Description of terms used to describe test effectiveness | 128 |
| 4.4.2 | Comparative clinical performance - gFOBT and iFOBT | 130 |
| 4.4.3 | Optimising clinical performance using test cut-off limits & algorithms | 133 |
| 4.4.3.1 | Cut-off limits | 133 |
| 4.4.3.2 | Number of stool specimens | 133 |
| 4.4.3.3 | Sequential testing | 136 |
| 4.4.3.4 | Participation rate and choice of test | 136 |
| 4.4.4 | Recommendations | 136 |
| 4.5 | Conclusions | 137 |
| 4.6 | References | 138 |

5

Quality assurance in endoscopy in colorectal cancer screening and diagnosis **145**

| | | |
|--------------|--|------------|
| | Guiding principles for a colorectal screening endoscopy service | 147 |
| | Recommendations | 148 |
| 5.1 | Effect of screening modality on the provision of endoscopic services for screening | 151 |
| 5.1.1 | Clinical setting | 151 |
| 5.1.2 | Quality and safety | 151 |
| 5.1.3 | The need for sedation | 153 |
| 5.1.4 | Patient considerations | 154 |
| 5.1.5 | Possible destabilising effect on symptomatic services | 154 |
| 5.1.6 | Infrastructure and efficiency | 154 |
| 5.1.7 | Endoscopist and support staff competencies | 154 |
| 5.1.8 | Support services | 155 |
| 5.1.9 | Conclusion | 155 |
| 5.2 | Audit and quality improvement | 155 |
| 5.3 | Before the procedure | 156 |
| 5.3.1 | Patient information and consent | 156 |
| 5.3.2 | Pre-assessment | 157 |
| 5.3.3 | Colonic cleansing | 157 |
| 5.3.4 | Scheduling and choice | 159 |
| 5.3.5 | Timelines | 159 |
| 5.3.6 | Environment | 159 |
| 5.4 | During the procedure | 160 |
| 5.4.1 | Cleansing and disinfection | 160 |
| 5.4.2 | Kit - technologies for improving insertion of the colonoscope | 161 |
| 5.4.3 | Kit – techniques and technologies to enhance detection, characterisation and removal of high-risk lesions | 161 |
| 5.4.4 | Sedation and comfort | 164 |
| 5.4.5 | Endoscopist techniques and performance | 166 |
| 5.4.5.1 | Quality outcomes | 166 |
| 5.4.5.2 | Safety outcomes | 169 |

| | | |
|------------------|--|------------|
| 5.5 | After the procedure | 170 |
| 5.5.1 | Recovery facilities and procedures | 170 |
| 5.5.2 | Emergency equipment and protocols | 170 |
| 5.5.3 | Patient information – post procedure | 170 |
| 5.5.4 | Patient feedback | 170 |
| 5.5.5 | Communication to other health professionals | 171 |
| 5.5.6 | Immediate and late safety outcomes | 171 |
| 5.6 | Guidelines | 171 |
| 5.7 | Policies and processes | 172 |
| 5.8 | References | 173 |
| Annex 5.1 | Suggested quality indicators and auditable outcomes | 179 |
| Annex 5.2 | Minimum requirements for endoscopic reporting | 183 |
| 6 | Professional requirements and training | 187 |
| | Recommendations | 189 |
| 6.1 | Introduction | 191 |
| 6.2 | General requirements | 191 |
| 6.3 | Administrative and clerical staff | 193 |
| 6.4 | Epidemiologist | 194 |
| 6.5 | Laboratory staff | 195 |
| 6.6 | Primary care physicians | 196 |
| 6.7 | Endoscopists | 197 |
| 6.8 | Radiologists | 199 |
| 6.9 | Pathologists | 199 |
| 6.10 | Surgeons | 201 |
| 6.11 | Nurses | 202 |
| 6.12 | Public health | 202 |
| 6.13 | References | 204 |

| | | |
|--------------|---|------------|
| 7 | Quality assurance in pathology in colorectal cancer screening and diagnosis | 205 |
| | Recommendations | 207 |
| 7.1 | Introduction | 209 |
| 7.2 | Classification of lesions in the adenoma-carcinoma sequence | 210 |
| 7.2.1 | Measurement of size of adenomas | 210 |
| 7.2.2 | Tubular, tubulo-villous and villous adenomas: the typing of villousness | 211 |
| 7.2.3 | Non-polypoid adenomas | 211 |
| 7.2.4 | Serrated lesions | 212 |
| 7.2.4.1 | Terminology | 212 |
| 7.2.4.2 | Hyperplastic (metaplastic) polyp | 212 |
| 7.2.4.3 | Sessile serrated lesions | 212 |
| 7.2.4.4 | Traditional serrated adenomas | 213 |
| 7.2.4.5 | Mixed polyp | 213 |
| 7.3 | Grading of neoplasia | 213 |
| 7.3.1 | Low-grade neoplasia | 213 |
| 7.3.2 | High-grade neoplasia | 214 |
| 7.4 | Other lesions | 216 |
| 7.4.1 | Inflammatory polyps | 216 |
| 7.4.2 | Juvenile polyps | 216 |
| 7.4.3 | Peutz-Jeghers polyps | 216 |
| 7.4.4 | Serrated (hyperplastic) polyposis | 217 |
| 7.4.5 | Cronkhite-Canada syndrome | 217 |
| 7.4.6 | Neuroendocrine tumour | 217 |
| 7.4.7 | Colorectal intramucosal tumours with epithelial entrapment and surface serration | 217 |
| 7.4.8 | Non epithelial polyps | 217 |
| 7.5 | Assessment of the degree of invasion of pT1 colorectal cancer | 218 |
| 7.5.1 | Definition of invasion | 218 |
| 7.5.2 | Epithelial misplacement | 218 |
| 7.5.3 | High risk pT1 adenocarcinoma | 219 |
| 7.5.3.1 | Sub-staging pT1 | 219 |
| 7.5.3.2 | Tumour grade in pT1 lesions | 220 |
| 7.5.3.3 | Lymphovascular invasion in pT1 adenocarcinomas | 220 |
| 7.5.3.4 | Margin involvement in pT1 adenocarcinomas | 221 |
| 7.5.3.5 | Tumour cell budding in pT1 adenocarcinomas | 221 |
| 7.5.3.6 | Site | 221 |
| 7.6 | Specimen handling | 221 |
| 7.6.1 | Submission of specimens | 222 |
| 7.6.2 | Fixation | 222 |
| 7.6.3 | Dissection | 222 |
| 7.6.3.1 | Polypoid lesions | 222 |
| 7.6.3.2 | Mucosal excisions | 222 |
| 7.6.3.3 | Piecemeal removal | 223 |

| | | |
|--------------|---|------------|
| 7.6.4 | Sectioning and levels | 223 |
| 7.6.5 | Surgically-removed lesions | 223 |
| 7.6.5.1 | Classification | 223 |
| 7.6.5.2 | Practical issues | 226 |
| 7.7 | Standards and quality indicators | 226 |
| 7.8 | Data collection and monitoring | 227 |
| 7.9 | Images | 228 |
| 7.10 | References | 229 |

7A **Annex - Annotations of colorectal lesions** **233**

| | | |
|-------------|---|------------|
| 7A.1 | Introduction | 235 |
| 7A.2 | Grading of neoplasia | 235 |
| 7A.3 | Classification of serrated lesions | 236 |
| 7A.3.1 | Terminology | 236 |
| 7A.3.2 | Hyperplastic polyp | 237 |
| 7A.3.3 | Sessile serrated lesion | 238 |
| 7A.3.4 | Traditional serrated adenoma | 240 |
| 7A.3.5 | Mixed polyp | 241 |
| 7A.3.6 | Risk of progression | 241 |
| 7A.4 | Assessment of T1 adenocarcinoma | 241 |
| 7A.4.1 | Size | 242 |
| 7A.4.2 | Tumour grade | 242 |
| 7A.4.3 | Budding | 242 |
| 7A.4.4 | Site | 242 |
| 7A.4.5 | Definition of invasion | 244 |
| 7A.5 | References | 246 |

8 **Management of lesions detected in colorectal cancer screening** **251**

| | | |
|------------|---|------------|
| | Recommendations | 253 |
| 8.1 | Introduction | 256 |
| 8.2 | General requirements for treatment of colorectal cancers and pre-malignant lesions | 256 |
| 8.3 | Management of pre-malignant colorectal lesions | 257 |
| 8.3.1 | Small lesions | 257 |

| | | |
|--------------|---|------------|
| 8.3.2 | Pedunculated adenomas/polyps | 258 |
| 8.3.3 | Large sessile colonic adenomas/lesions | 258 |
| 8.3.4 | Large sessile rectal adenomas/lesions | 258 |
| 8.3.5 | Retrieval of lesions | 259 |
| 8.3.6 | Management of incomplete endoscopic excision | 259 |
| 8.3.7 | Management of pre-malignant lesions in patients taking anti-coagulants/anti-aggregants | 259 |
| 8.3.8 | Synopsis | 260 |
| 8.4 | Management of pT1 cancers | 261 |
| 8.4.1 | Primary management | 261 |
| 8.4.2 | Completion surgery | 262 |
| 8.4.3 | Follow-up | 262 |
| 8.4.4 | Synopsis | 263 |
| 8.5 | Management of colon cancer | 263 |
| 8.5.1 | Preoperative staging | 263 |
| 8.5.2 | Surgery | 264 |
| 8.5.3 | Synopsis | 264 |
| 8.6 | Management of rectal cancer | 265 |
| 8.6.1 | Pre-operative staging | 265 |
| 8.6.2 | Neoadjuvant therapy | 265 |
| 8.6.3 | Surgery | 266 |
| 8.6.4 | Post-operative radiotherapy | 266 |
| 8.6.5 | Management of small rectal cancers | 266 |
| 8.6.6 | Synopsis | 267 |
| 8.7 | References | 269 |
| 9 | Colonoscopy surveillance following adenoma removal | 273 |
| | Guiding principles | 275 |
| | Recommendations | 276 |
| 9.1 | Introduction | 280 |
| 9.2 | Risk factors for advanced adenomas and cancer after baseline removal of adenomas | 281 |
| 9.2.1 | Procedural factors | 281 |
| 9.2.1.1 | Quality of colonoscopy | 281 |
| 9.2.1.2 | Incomplete or inadequate colonoscopy | 282 |
| 9.2.1.3 | Management of incomplete adenoma excision | 282 |
| 9.2.2 | Characteristics of baseline adenomas | 282 |
| 9.2.2.1 | Number of adenomas | 282 |
| 9.2.2.2 | Size of adenomas | 283 |
| 9.2.2.3 | Adenoma histology | 283 |
| 9.2.2.4 | Grade of neoplasia | 284 |
| 9.2.2.5 | Location | 284 |

| | | |
|---------------|---|------------|
| 9.2.3 | Patient characteristics | 284 |
| 9.2.3.1 | Age and sex | 284 |
| 9.2.3.2 | Family history | 285 |
| 9.3 | Risk groups and surveillance intervals | 285 |
| 9.3.1 | Low risk group | 286 |
| 9.3.2 | Intermediate risk group | 287 |
| 9.3.3 | High risk group | 287 |
| 9.4 | Adjusting surveillance during follow-up | 287 |
| 9.4.1 | Significance of a normal surveillance colonoscopy | 288 |
| 9.4.2 | Stopping surveillance | 288 |
| 9.4.3 | Symptoms developing between surveillance exams | 289 |
| 9.4.4 | Role of faecal occult blood testing | 289 |
| 9.5 | Colonoscopic surveillance guidelines following removal of other colorectal lesions | 289 |
| 9.5.1 | Locally removed pT1 cancers | 289 |
| 9.5.2 | Serrated adenomas | 290 |
| 9.5.3 | Hyperplastic polyps and other non-neoplastic serrated lesions | 290 |
| 9.6 | Opportunity costs | 290 |
| 9.7 | Quality standards and auditable outcomes | 291 |
| 9.7.1 | Adherence to the guideline | 291 |
| 9.7.2 | Timeliness of surveillance procedures | 292 |
| 9.7.3 | Incident cancers | 292 |
| 9.8 | References | 293 |
| 10 | Communication | 299 |
| | Recommendations | 301 |
| 10.1 | Introduction | 304 |
| 10.1.1 | Using communication strategies for a colorectal cancer screening programme: goals and challenges | 304 |
| 10.1.2 | Purpose of this chapter | 304 |
| 10.2 | General principles | 305 |
| 10.2.1 | Informed decision-making, ethical principles | 305 |
| 10.2.2 | Identifying and reducing barriers/obstacles to informed decision making | 305 |
| 10.2.2.1 | Barriers related to the patients themselves | 306 |
| 10.2.2.2 | Reducing barriers | 307 |
| 10.3 | Communication tools/Interventions used in CRC screening programmes | 308 |

| | | |
|---------------|---|------------|
| 10.4 | Effectiveness of communication interventions in CRC screening | 310 |
| 10.4.1 | Interventions used to invite a person undergo the test | 310 |
| 10.4.1.1 | Physician/GP endorsement | 310 |
| 10.4.1.2 | Letters | 310 |
| 10.4.1.3 | FOBT: delivery of the kit and instruction sheet | 311 |
| 10.4.2 | Other interventions which can be used with the invitation: written, visual, face-to-face interventions | 311 |
| 10.4.2.1 | Leaflets and booklets | 311 |
| 10.4.2.2 | Videotapes/DVDs, interactive computer-based decision aids, ICTs (information & communication technologies) and Internet | 313 |
| 10.4.2.2.1 | Videotapes/DVDs | 313 |
| 10.4.2.2.2 | Interactive computer-based decision aids | 315 |
| 10.4.2.2.3 | Information and communication technologies: future promises and challenges for enhancing CRC screening delivery | 315 |
| 10.4.2.2.4 | Internet | 317 |
| 10.4.2.3 | Telephone intervention, patient navigator (PN) intervention, and verbal face-to-face intervention other than PN | 318 |
| 10.4.2.3.1 | Telephone intervention | 318 |
| 10.4.2.3.2 | Patient navigation/patient navigator | 319 |
| 10.4.2.3.3 | Verbal face-to-face intervention other than PN: verbal face-to-face with GP, nurse or other health or trained non-health professional | 320 |
| 10.4.2.4 | Mass media campaigns | 322 |
| 10.4.2.5 | Advocacy groups | 323 |
| 10.4.3 | Communication tools/interventions used to inform a person of a screening test result and facilitate follow-up of a positive result | 323 |
| 10.5 | Content that should be included in: the invitation letter and leaflet, the letter and leaflet used to notify results, and the instructions | 325 |
| 10.5.1 | General recommendations | 325 |
| 10.5.2 | When FOBT is used for screening: content of letters and leaflets | 326 |
| 10.5.2.1 | FOBT invitation letter | 326 |
| 10.5.2.2 | FOBT invitation leaflet | 327 |
| 10.5.2.3 | FOBT result/follow-up letter | 329 |
| 10.5.2.4 | Colonoscopy leaflet (see Section 10.5.3.2) | 329 |
| 10.5.3 | When flexible sigmoidoscopy (FS) or colonoscopy is used for screening, either as primary screening test (FS or CS) or to follow-up a positive FOBT result (only CS): content of letters and leaflets | 329 |
| 10.5.3.1 | Endoscopy invitation letter | 329 |
| 10.5.3.2 | Endoscopy invitation leaflet: example for colonoscopy | 330 |
| 10.5.3.3 | Endoscopy results/follow-up letter | 331 |
| 10.6 | Stylistic advice | 331 |
| 10.7 | Evaluating the quality of public information materials: are these materials meeting the required standard for quality? | 333 |
| 10.8 | References | 334 |

Appendices

| | | |
|-------------------|--|------------|
| Appendix 1 | Systematic evidence review – Summary documents and evidence tables for key clinical questions | 341 |
| Appendix 2 | Council Recommendation of 2 December 2003 on cancer screening (2003/878/EC) | 345 |
| Appendix 3 | Report from the Commission to the Council, the European Parliament, the European Economic and Social Committee and the Committee of the Regions Implementation of the Council Recommendation of 2 December 2003 on cancer screening (2003/878/EC) | 353 |
| Appendix 4 | List of websites | 367 |
| | List of tables and figures | 371 |
| | List of abbreviations | 375 |
| | Glossary of terms | 381 |